HC Wainwright Issues Pessimistic Outlook for CMPS Earnings

Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS) – Stock analysts at HC Wainwright decreased their Q3 2026 EPS estimates for Compass Pathways in a report released on Friday, August 7th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings per share of ($0.43) for the quarter, down from their previous forecast of ($0.40). HC Wainwright currently has a “Buy” rating and a $65.00 target price on the stock. The consensus estimate for Compass Pathways’ current full-year earnings is ($1.25) per share. HC Wainwright also issued estimates for Compass Pathways’ Q4 2026 earnings at ($0.48) EPS, FY2026 earnings at ($1.58) EPS, Q2 2027 earnings at ($0.41) EPS, Q3 2027 earnings at ($0.39) EPS, Q4 2027 earnings at ($0.36) EPS, FY2027 earnings at ($1.56) EPS, FY2028 earnings at ($0.23) EPS, FY2029 earnings at $1.66 EPS and FY2030 earnings at $4.06 EPS.

Compass Pathways (NASDAQ:CMPS) last announced its quarterly earnings results on Wednesday, August 5th. The company reported ($1.88) EPS for the quarter, missing analysts’ consensus estimates of ($0.39) by ($1.49).

Several other equities research analysts also recently issued reports on CMPS. Evercore upgraded Compass Pathways from an “in-line” rating to an “outperform” rating and set a $21.00 target price on the stock in a research report on Wednesday, July 8th. Royal Bank Of Canada dropped their price objective on Compass Pathways from $22.00 to $21.00 and set an “outperform” rating on the stock in a report on Thursday. Stifel Nicolaus lifted their target price on Compass Pathways from $14.00 to $21.00 and gave the company a “buy” rating in a report on Tuesday, July 7th. Weiss Ratings reissued a “sell (d-)” rating on shares of Compass Pathways in a report on Friday, July 17th. Finally, Morgan Stanley boosted their price objective on shares of Compass Pathways from $17.00 to $18.00 and gave the company an “overweight” rating in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, Compass Pathways presently has an average rating of “Moderate Buy” and an average target price of $23.36.

Compass Pathways Stock Down 2.7%

Compass Pathways stock opened at $13.18 on Tuesday. Compass Pathways has a 1-year low of $3.97 and a 1-year high of $15.40. The firm has a market capitalization of $1.78 billion, a price-to-earnings ratio of -2.85 and a beta of 2.50. The company has a current ratio of 1.30, a quick ratio of 1.30 and a debt-to-equity ratio of 0.60. The firm has a 50 day simple moving average of $12.57 and a 200 day simple moving average of $9.39.

Institutional Inflows and Outflows

Several institutional investors have recently modified their holdings of CMPS. Toronto Dominion Bank raised its stake in Compass Pathways by 152.9% in the fourth quarter. Toronto Dominion Bank now owns 2,529,013 shares of the company’s stock valued at $17,447,000 after purchasing an additional 1,529,013 shares in the last quarter. Nantahala Capital Management LLC increased its holdings in shares of Compass Pathways by 47.7% in the 2nd quarter. Nantahala Capital Management LLC now owns 4,179,930 shares of the company’s stock worth $11,704,000 after buying an additional 1,350,698 shares during the last quarter. Ameriprise Financial Inc. purchased a new stake in shares of Compass Pathways during the 3rd quarter valued at $6,926,000. Orbimed Advisors LLC purchased a new stake in shares of Compass Pathways during the 1st quarter valued at $6,363,000. Finally, Siren L.L.C. bought a new stake in shares of Compass Pathways during the 4th quarter worth $6,900,000. 46.19% of the stock is currently owned by institutional investors.

Key Stories Impacting Compass Pathways

Here are the key news stories impacting Compass Pathways this week:

• Positive Sentiment: HC Wainwright maintained its Buy rating and $65 price target, substantially above the stock’s recent trading level. The firm still projects a potential transition to profitability, including estimated earnings of $1.66 per share in 2029 and $4.06 in 2030.
• Neutral Sentiment: The analyst now forecasts losses of $0.43 per share in the third quarter of 2026, $0.48 in the fourth quarter, and $1.58 for full-year 2026. Estimates remain negative through 2028, suggesting Compass Pathways is still dependent on successful clinical development and eventual commercialization of its pipeline.
• Negative Sentiment: HC Wainwright cut its 2027 EPS forecast to a $1.56 loss from an $0.85 loss, and reduced its 2028 forecast to a $0.23 loss from previously estimated earnings of $1.64 per share. The firm also lowered 2029 EPS to $1.66 from $3.78 and 2030 EPS to $4.06 from $6.59. Near-term quarterly estimates were also reduced, including Q2 2027 to a $0.41 loss, Q3 2027 to a $0.39 loss, and Q4 2027 to a $0.36 loss. These sharp cuts point to higher projected expenses, delayed revenue generation, or a slower-than-expected commercial ramp.

About Compass Pathways

Compass Pathways (NASDAQ: CMPS) is a clinical-stage biotechnology company focused on the development and commercialization of psilocybin therapy for mental health disorders. Founded in 2016 and headquartered in London with additional offices in the United States, Compass Pathways is pioneering the use of synthetic psilocybin combined with psychotherapy to address treatment-resistant depression. The company’s flagship program is a Phase IIb clinical trial evaluating COMP360, its proprietary psilocybin formulation, which has received Breakthrough Therapy designation from the U.S.